Analysis of the CΥP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population

被引:107
作者
Tateishi, T
Chida, M
Ariyoshi, N
Mizorogi, Y
Kamataki, T
Kobayashi, S
机构
[1] St Marianna Univ, Sch Med, Dept Pharmacol, Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan
[2] Hokkaido Univ, Grad Sch Pharmaceut Sci, Div Pharmacobiodynam, Lab Drug Metab, Sapporo, Hokkaido 060, Japan
[3] Tokokai Daiichi Hosp, Clin Pharmacol Ctr, Tokyo, Japan
关键词
D O I
10.1016/S0009-9236(99)70077-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To analyze the CYP2D6 allele frequencies in a Japanese population and to evaluate the effects of CYP2D6 variants on in vivo CYP2D6 activity as measured by the dextromethorphan metabolic ratio (MR). Methods: Ninety-eight unrelated, healthy Japanese men were phenotyped with dextromethorphan and genotyped by the polymerase chain reaction amplification method for 7 CYP2D6 alleles. Results:The CYP2D6*1, CYP2D6*10 CYP2D6*2 CYP2D6*5, CYP2D6*4, and CYP2D6*21 allele frequencies in our Japanese subjects were 0.423, 0.408, 0.092, 0.061, 0.020, and 0.010, respectively. Thirty-three subjects (33.7%) were heterozygous for *10/*1, and 18 (18.4%) and 17 (17.3%) subjects were homozygous for *1 and *10 respectively. Subjects who were homozygous for *10 showed the highest dextromethorphan MR among these 3 genotypes. Eighteen subjects (18.3%) were heterozygous for *2 but their dextromethorphan MR values were not greater than the MR values of subjects who were homozygous for *1. One subject was a poor metabolizer phenotypically, and he was homozygous for *5. Conclusions The CYP2D6 allele frequencies in our Japanese subjects differed from those determined in previous studies of white subjects or mainland Chinese subjects. Individuals homozygous for *10 who have relatively low in vivo CYP2D6 activity represent almost 20% of the Japanese population. In addition, we did not identify any subjects with amplified *2 among our 98 Japanese men.
引用
收藏
页码:570 / 575
页数:6
相关论文
共 24 条
  • [1] GENETIC-BASIS FOR DIFFERENCES IN DEBRISOQUIN POLYMORPHISM BETWEEN A SPANISH AND OTHER WHITE-POPULATIONS
    AGUNDEZ, JAG
    MARTINEZ, C
    LEDESMA, MC
    LADONA, MG
    LADERO, JM
    BENITEZ, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (04) : 412 - 417
  • [2] PREVALENCE OF CYP2D6 GENE DUPLICATION AND ITS REPERCUSSION ON THE OXIDATIVE PHENOTYPE IN A WHITE-POPULATION
    AGUNDEZ, JAG
    LEDESMA, MC
    LADERO, JM
    BENITEZ, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) : 265 - 269
  • [3] Aklillu E, 1996, J PHARMACOL EXP THER, V278, P441
  • [4] THE CYTOCHROME-P450 CYP2D6 ALLELIC VARIANT CYP2D6J AND RELATED POLYMORPHISMS IN A EUROPEAN POPULATION
    ARMSTRONG, M
    FAIRBROTHER, K
    IDLE, JR
    DALY, AK
    [J]. PHARMACOGENETICS, 1994, 4 (02): : 73 - 81
  • [5] High performance liquid chromatography determination of dextromethorphan and its metabolites in urine using solid-phase extraction
    Bartoletti, RA
    Belpaire, FM
    Rosseel, MT
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1996, 14 (8-10) : 1281 - 1286
  • [6] GEOGRAPHICAL INTERRACIAL DIFFERENCES IN POLYMORPHIC DRUG OXIDATION - CURRENT STATE OF KNOWLEDGE OF CYTOCHROMES P450 (CYP) 2D6 AND 2C19
    BERTILSSON, L
    [J]. CLINICAL PHARMACOKINETICS, 1995, 29 (03) : 192 - 209
  • [7] DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION
    BROLY, F
    GAEDIGK, A
    HEIM, M
    EICHELBAUM, M
    MORIKE, K
    MEYER, UA
    [J]. DNA AND CELL BIOLOGY, 1991, 10 (08) : 545 - 558
  • [8] GENETIC-ANALYSIS OF THE CYP2D LOCUS IN RELATION TO DEBRISOQUINE HYDROXYLATION CAPACITY IN KOREAN, JAPANESE AND CHINESE SUBJECTS
    DAHL, ML
    YUE, QY
    ROH, HK
    JOHANSSON, I
    SAWE, J
    SJOQVIST, F
    BERTILSSON, L
    [J]. PHARMACOGENETICS, 1995, 5 (03): : 159 - 164
  • [9] DAHL ML, 1995, J PHARMACOL EXP THER, V274, P516
  • [10] Nomenclature for human CYP2D6 alleles
    Daly, AK
    Brockmoller, J
    Broly, F
    Eichelbaum, M
    Evans, WE
    Gonzalez, FJ
    Huang, JD
    Idle, JR
    IngelmanSundberg, M
    Ishizaki, T
    JacqzAigrain, E
    Meyer, UA
    Nebert, DW
    Steen, VM
    Wolf, CR
    Zanger, UM
    [J]. PHARMACOGENETICS, 1996, 6 (03): : 193 - 201